HIV-1 Tat second exon limits the extent of Tat-mediated modulation of interferon-stimulated genes in antigen presenting cells

Retrovirology

Anna Aldovini¹  Mariana Manrique¹  Nayoung Kim¹  Maria Del Pilar Martinez-Viedma¹  Sami Kukkonen¹ 

[1]Department of Pediatrics, Harvard Medical School, Department of Medicine, Boston Children’s Hospital, 300 Longwood Avenue, Boston, MA 02115, USA

关键词: Antigen presenting cells (APC);    Human immunodeficiency virus type 1 (HIV-1);    Tat;    IFN-stimulated genes (ISG);    Monocyte-derived macrophages (MDM);    Immature dendritic cells (iDC);   

Others  :  802053
DOI  :  10.1186/1742-4690-11-30

 received in 2013-10-15, accepted in 2014-03-27,  发布年份 2014

【 摘 要 】

Background

We have shown that HIV-1 Tat interaction with MAP2K3, MAP2K6, and IRF7 promoters is key to IFN-stimulated genes (ISG) activation in immature dendritic cells and macrophages.

Results

We evaluated how Tat alleles and mutants differ in cellular gene modulation of immature dendritic cells and monocyte-derived macrophages and what similarities this modulation has with that induced by interferons. The tested alleles and mutants modulated to different degrees ISG, without concomitant induction of interferons. The first exon Tat_SF21-72 and the minimal transactivator Tat_SF21-58, all modulated genes to a significantly greater extent than full-length wild type, two-exon Tat, indicating that Tat second exon is critical in reducing the innate response triggered by HIV-1 in these cells. Mutants with reduced LTR transactivation had a substantially reduced effect on host gene expression modulation than wild type Tat_SF2. However, the more potent LTR transactivator Tat_SF2A58T modulated ISG expression to a lower degree compared to Tat_SF2. A cellular gene modulation similar to that induced by Tat and Tat mutants in immature dendritic cells could be observed in monocyte-derived macrophages, with the most significant pathways affected by Tat being the same in both cell types. Tat expression in cells deleted of the type I IFN locus or receptor resulted in a gene modulation pattern similar to that induced in primary immature dendritic cells and monocyte-derived macrophages, excluding the involvement of type I IFNs in Tat-mediated gene modulation. ISG activation depends on Tat interaction with MAP2K3, MAP2K6, and IRF7 promoters and a single exon Tat protein more strongly modulated the luciferase activity mediated by MAP2K3, MAP2K6, and IRF7 promoter sequences located 5′ of the RNA start site than the wild type two-exon Tat, while a cysteine and lysine Tat mutants, reduced in LTR transactivation, had negligible effects on these promoters. Chemical inhibition of CDK9 or Sp1 decreased Tat activation of MAP2K3-, MAP2K6-, and IRF7-mediated luciferase transcription.

Conclusions

Taken together, these data indicate that the second exon of Tat is critical to the containment of the innate response stimulated by Tat in antigen presenting cells and support a role for Tat in stimulating cellular transcription via its interaction with transcription factors present at promoters.

【 授权许可】

   
2014 Kukkonen et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Fig. 3.

Figure 6.

【 参考文献 】

• [1]Kao SY, Calman AF, Luciw PA, Peterlin BM: Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product. Nature 1987, 330:489-493.
• [2]Garber ME, Jones KA: HIV-1 Tat: coping with negative elongation factors. Curr Opin Immunol 1999, 11:460-465.
• [3]Jones KA: Taking a new TAK on tat transactivation. Genes Dev 1997, 11:2593-2599.
• [4]Zhou Q, Sharp PA: Tat-SF1: cofactor for stimulation of transcriptional elongation by HIV-1 Tat. Science 1996, 274:605-610.
• [5]Wu Y, Marsh JW: Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA. Science 2001, 293:1503-1506.
• [6]Garcia JA, Harrich D, Pearson L, Mitsuyasu R, Gaynor RB: Functional domains required for tat-induced transcriptional activation of the HIV-1 long terminal repeat. EMBO J 1988, 7:3143-3147.
• [7]Kuppuswamy M, Subramanian T, Srinivasan A, Chinnadurai G: Multiple functional domains of Tat, the trans-activator of HIV-1, defined by mutational analysis. Nucleic Acids Res 1989, 17:3551-3561.
• [8]Rice AP, Carlotti F: Mutational analysis of the conserved cysteine-rich region of the human immunodeficiency virus type 1 Tat protein. J Virol 1990, 64:1864-1868.
• [9]Mahlknecht U, Dichamp I, Varin A, Van Lint C, Herbein G: NF-kappaB-dependent control of HIV-1 transcription by the second coding exon of Tat in T cells. J Leukoc Biol 2008, 83:718-727.
• [10]Viglianti GA, Mullins JI: Functional comparison of transactivation by simian immunodeficiency virus from rhesus macaques and human immunodeficiency virus type 1. J Virol 1988, 62:4523-4532.
• [11]Tong-Starksen SE, Baur A, Lu XB, Peck E, Peterlin BM: Second exon of Tat of HIV-2 is required for optimal trans-activation of HIV-1 and HIV-2 LTRs. Virology 1993, 195:826-830.
• [12]Smith SM, Pentlicky S, Klase Z, Singh M, Neuveut C, Lu CY, Reitz MS Jr, Yarchoan R, Marx PA, Jeang KT: An in vivo replication-important function in the second coding exon of Tat is constrained against mutation despite cytotoxic T lymphocyte selection. J Biol Chem 2003, 278:44816-44825.
• [13]Dingwall C, Ernberg I, Gait MJ, Green SM, Heaphy S, Karn J, Lowe AD, Singh M, Skinner MA: HIV-1 tat protein stimulates transcription by binding to a U-rich bulge in the stem of the TAR RNA structure. Embo J 1990, 9:4145-4153.
• [14]Fong YW, Zhou Q: Relief of two built-In autoinhibitory mechanisms in P-TEFb is required for assembly of a multicomponent transcription elongation complex at the human immunodeficiency virus type 1 promoter. Mol Cell Biol 2000, 20:5897-5907.
• [15]Garber ME, Mayall TP, Suess EM, Meisenhelder J, Thompson NE, Jones KA: CDK9 autophosphorylation regulates high-affinity binding of the human immunodeficiency virus type 1 tat-P-TEFb complex to TAR RNA. Mol Cell Biol 2000, 20:6958-6969.
• [16]Rice AP, Chan F: Tat protein of human immunodeficiency virus type 1 is a monomer when expressed in mammalian cells. Virology 1991, 185:451-454.
• [17]Zhou C, Rana TM: A bimolecular mechanism of HIV-1 Tat protein interaction with RNA polymerase II transcription elongation complexes. J Mol Biol 2002, 320:925-942.
• [18]Zhu Y, Pe’ery T, Peng J, Ramanathan Y, Marshall N, Marshall T, Amendt B, Mathews MB, Price DH: Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes Dev 1997, 11:2622-2632.
• [19]Marzio G, Giacca M: Chromatin control of HIV-1 gene expression. Genetica 1999, 106:125-130.
• [20]Sune C, Garcia-Blanco MA: Sp1 transcription factor is required for in vitro basal and Tat-activated transcription from the human immunodeficiency virus type 1 long terminal repeat. J Virol 1995, 69:6572-6576.
• [21]Chun RF, Semmes OJ, Neuveut C, Jeang KT: Modulation of Sp1 phosphorylation by human immunodeficiency virus type 1 Tat. J Virol 1998, 72:2615-2629.
• [22]Chang JR, Mukerjee R, Bagashev A, Del Valle L, Chabrashvili T, Hawkins BJ, He JJ, Sawaya BE: HIV-1 Tat protein promotes neuronal dysfunction through disruption of microRNAs. J Biol Chem 2011, 286:41125-41134.
• [23]Izmailova E, Bertley FM, Huang Q, Makori N, Miller CJ, Young RA, Aldovini A: HIV-1 Tat reprograms immature dendritic cells to express chemoattractants for activated T cells and macrophages. Nat Med 2003, 9:191-197.
• [24]New DR, Ma M, Epstein LG, Nath A, Gelbard HA: Human immunodeficiency virus type 1 Tat protein induces death by apoptosis in primary human neuron cultures. J Neurovirol 1997, 3:168-173.
• [25]Viscidi RP, Mayur K, Lederman HM, Frankel AD: Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1. Science 1989, 246:1606-1608.
• [26]Zagury D, Lachgar A, Chams V, Fall LS, Bernard J, Zagury JF, Bizzini B, Gringeri A, Santagostino E, Rappaport J, Feldman M, Burny A, Gallo RC: Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS. Proc Natl Acad Sci USA 1998, 95:3851-3856.
• [27]Kim N, Kukkonen S, Martinez-Viedma Mdel P, Gupta S, Aldovini A: Tat engagement of p38 MAP kinase and IRF7 pathways leads to activation of interferon-stimulated genes in antigen-presenting cells. Blood 2013, 121:4090-4100.
• [28]Kim N, Dabrowska A, Jenner RG, Aldovini A: Human and simian immunodeficiency virus-mediated upregulation of the apoptotic factor TRAIL occurs in antigen-presenting cells from AIDS-susceptible but not from AIDS-resistant species. J Virol 2007, 81:7584-7597.
• [29]Dabrowska A, Kim N, Aldovini A: Tat-induced FOXO3a is a key mediator of apoptosis in HIV-1-infected human CD4+ T lymphocytes. J Immunol 2008, 181:8460-8477.
• [30]LeGuern M, Shioda T, Levy JA, Cheng-Mayer C: Single amino acid change in Tat determines the different rates of replication of two sequential HIV-1 isolates. Virology 1993, 195:441-447.
• [31]Green M, Ishino M, Loewenstein PM: Mutational analysis of HIV-1 Tat minimal domain peptides: identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression. Cell 1989, 58:215-223.
• [32]Derse D, Carvalho M, Carroll R, Peterlin BM: A minimal lentivirus Tat. J Virol 1991, 65:7012-7015.
• [33]Kiernan RE, Vanhulle C, Schiltz L, Adam E, Xiao H, Maudoux F, Calomme C, Burny A, Nakatani Y, Jeang KT, Benkirane M, Van Lint C: HIV-1 tat transcriptional activity is regulated by acetylation. EMBO J 1999, 18:6106-6118.
• [34]Col E, Caron C, Seigneurin-Berny D, Gracia J, Favier A, Khochbin S: The histone acetyltransferase, hGCN5, interacts with and acetylates the HIV transactivator, Tat. J Biol Chem 2001, 276:28179-28184.
• [35]Wong K, Sharma A, Awasthi S, Matlock EF, Rogers L, Van Lint C, Skiest DJ, Burns DK, Harrod R: HIV-1 Tat interactions with p300 and PCAF transcriptional coactivators inhibit histone acetylation and neurotrophin signaling through CREB. J Biol Chem 2005, 280:9390-9399.
• [36]Hauber J, Malim MH, Cullen BR: Mutational analysis of the conserved basic domain of human immunodeficiency virus tat protein. J Virol 1989, 63:1181-1187.
• [37]Shaw GM, Hahn BH, Arya SK, Groopman JE, Gallo RC, Wong-Staal F: Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome. Science 1984, 226:1165-1171.
• [38]Chang SY, Bowman BH, Weiss JB, Garcia RE, White TJ: The origin of HIV-1 isolate HTLV-IIIB. Nature 1993, 363:466-469.
• [39]Gendelman HE, Friedman RM, Joe S, Baca LM, Turpin JA, Dveksler G, Meltzer MS, Dieffenbach C: A selective defect of interferon alpha production in human immunodeficiency virus-infected monocytes. J Exp Med 1990, 172:1433-1442.
• [40]Zhang M, Li X, Pang X, Ding L, Wood O, Clouse K, Hewlett I, Dayton AI: Identification of a potential HIV-induced source of bystander-mediated apoptosis in T cells: upregulation of trail in primary human macrophages by HIV-1 tat. J Biomed Sci 2001, 8:290-296.
• [41]Woelk CH, Ottones F, Plotkin CR, Du P, Royer CD, Rought SE, Lozach J, Sasik R, Kornbluth RS, Richman DD, Corbeil J: Interferon gene expression following HIV type 1 infection of monocyte-derived macrophages. AIDS Res Hum Retrovir 2004, 20:1210-1222.
• [42]Kim BO, Liu Y, Zhou BY, He JJ: Induction of C chemokine XCL1 (lymphotactin/single C motif-1 alpha/activation-induced, T cell-derived and chemokine-related cytokine) expression by HIV-1 Tat protein. J Immunol 2004, 172:1888-1895.
• [43]St Louis DC, Woodcock JB, Franzoso G, Blair PJ, Carlson LM, Murillo M, Wells MR, Williams AJ, Smoot DS, Kaushal S, Grimes JL, Harlan DM, Chute JP, June CH, Siebenlist U, Lee KP: Evidence for distinct intracellular signaling pathways in CD34+ progenitor to dendritic cell differentiation from a human cell line model. J Immunol 1999, 162:3237-3248.
• [44]Leung S, Qureshi SA, Kerr IM, Darnell JE Jr, Stark GR: Role of STAT2 in the alpha interferon signaling pathway. Mol Cell Biol 1995, 15:1312-1317.
• [45]Lutfalla G, Holland SJ, Cinato E, Monneron D, Reboul J, Rogers NC, Smith JM, Stark GR, Gardiner K, Mogensen KE: Mutant U5A cells are complemented by an interferon-alpha beta receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster. EMBO J 1995, 14:5100-5108.
• [46]Biglione S, Byers SA, Price JP, Nguyen VT, Bensaude O, Price DH, Maury W: Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex. Retrovirology 2007, 4:47. BioMed Central Full Text
• [47]Kutsch O, Levy DN, Bates PJ, Decker J, Kosloff BR, Shaw GM, Priebe W, Benveniste EN: Bis-anthracycline antibiotics inhibit human immunodeficiency virus type 1 transcription. Antimicrob Agents Chemother 2004, 48:1652-1663.
• [48]Martin B, Vaquero A, Priebe W, Portugal J: Bisanthracycline WP631 inhibits basal and Sp1-activated transcription initiation in vitro. Nucleic Acids Res 1999, 27:3402-3409.
• [49]Eberhardy SR, Farnham PJ: Myc recruits P-TEFb to mediate the final step in the transcriptional activation of the cad promoter. J Biol Chem 2002, 277:40156-40162.
• [50]Rahl PB, Lin CY, Seila AC, Flynn RA, McCuine S, Burge CB, Sharp PA, Young RA: c-Myc regulates transcriptional pause release. Cell 2010, 141:432-445.
• [51]Kane M, Yadav SS, Bitzegeio J, Kutluay SB, Zang T, Wilson SJ, Schoggins JW, Rice CM, Yamashita M, Hatziioannou T, Bieniasz PD: MX2 is an interferon-induced inhibitor of HIV-1 infection. Nature 2013, 502:563-566.
• [52]Goujon C, Moncorge O, Bauby H, Doyle T, Ward CC, Schaller T, Hue S, Barclay WS, Schulz R, Malim MH: Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection. Nature 2013, 502:559-562.
• [53]Sadler AJ, Williams BR: Interferon-inducible antiviral effectors. Nat Rev Immunol 2008, 8:559-568.
• [54]Silvestri G, Sodora DL, Koup RA, Paiardini M, O’Neil SP, McClure HM, Staprans SI, Feinberg MB: Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity 2003, 18:441-452.
• [55]Bosinger SE, Li Q, Gordon SN, Klatt NR, Duan L, Xu L, Francella N, Sidahmed A, Smith AJ, Cramer EM, Cramer EM, Zeng M, Masopust D, Carlis JV, Ran L, Vanderford TH, Paiardini M, Isett RB, Baldwin DA, Else JG, Staprans SI, Silvestri G, Haase AT, Kelvin DJ: Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. J Clin Invest 2009, 119:3556-3572.
• [56]Jacquelin B, Mayau V, Targat B, Liovat AS, Kunkel D, Petitjean G, Dillies MA, Roques P, Butor C, Silvestri G, Giavedoni LD, Lebon P, Barre-Sinoussi F, Benecke A, Muller-Trutwin MC: Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J Clin Invest 2009, 119:3544-3555.
• [57]Lederer S, Favre D, Walters KA, Proll S, Kanwar B, Kasakow Z, Baskin CR, Palermo R, McCune JM, Katze MG: Transcriptional profiling in pathogenic and non-pathogenic SIV infections reveals significant distinctions in kinetics and tissue compartmentalization. PLoS Pathog 2009, 5:e1000296.
• [58]Klatt NR, Silvestri G, Hirsch V: Nonpathogenic simian immunodeficiency virus infections. Cold Spring Harb Perspect Med 2012, 2:a007153.
• [59]Chartier C, Degryse E, Gantzer M, Dieterle A, Pavirani A, Mehtali M: Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol 1996, 70:4805-4810.
• [60]Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, Taira K, Akira S, Fujita T: The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004, 5:730-737.
• [61]Grander D, Heyman M, Brondum-Nielsen K, Liu Y, Lundgren E, Soderhall S, Einhorn S: Interferon system in primary acute lymphocytic leukemia cells with or without deletions of the alpha-/beta-interferon genes. Blood 1992, 79:2076-2083.
• [62]Colamonici OR, Domanski P, Platanias LC, Diaz MO: Correlation between interferon (IFN) alpha resistance and deletion of the IFN alpha/beta genes in acute leukemia cell lines suggests selection against the IFN system. Blood 1992, 80:744-749.
• [63]Yount JS, Moran TM, Lopez CB: Cytokine-independent upregulation of MDA5 in viral infection. J Virol 2007, 81:7316-7319.
• [64]Burnette WN: “Western blotting”: electrophoretic transfer of proteins from sodium dodecyl sulfate–polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal Biochem 1981, 112:195-203.